Cencora (COR) Stock Forecast & Price Target

Q: What analysts cover Cencora?

Cencora has been rated by research analysts at Citigroup , Evercore , JPMorgan Chase & Co. , Morgan Stanley , Robert W. Baird , Royal Bank Of Canada , UBS Group , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$303.84 +0.03 (+0.01%)

As of 01:11 PM Eastern

Compare

Cencora - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
0

Hold
3

Buy
13

Based on 16 Wall Street analysts who have issued ratings for Cencora in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 3 have given a hold rating, and 13 have given a buy rating for COR.

Consensus Price Target

$370.85
22.05% Upside

According to the 16 analysts' twelve-month price targets for Cencora, the average price target is $370.85. The highest price target for COR is $440.00, while the lowest price target for COR is $285.00. The average price target represents a forecasted upside of 22.05% from the current price of $303.84.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for COR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cencora and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

COR Analyst Ratings Over Time

Type	Current Forecast 9/29/25 to 9/29/26	1 Month Ago 8/30/25 to 8/30/26	3 Months Ago 7/1/25 to 7/1/26	1 Year Ago 9/29/24 to 9/29/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	13 Buy rating(s)	11 Buy rating(s)	10 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$370.85	$370.85	$367.75	$311.25
Forecasted Upside	22.05% Upside	15.13% Upside	27.60% Upside	1.02% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

COR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

COR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cencora Stock vs. The Competition

Type	Cencora	Healthcare Companies	Broader Market
Consensus Rating Score	2.81	2.31	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	22.20% Upside	780.06% Upside	19.95% Upside
News Sentiment Rating	Positive News See Recent COR News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/8/2026	Royal Bank Of Canada 3 of 5 stars	Ryan Halsted Not Rated	Reiterated Rating	Sector Perform	$330.00	+0.91%
8/11/2026	Wells Fargo & Company 3 of 5 stars	Stephen Baxter 4 of 5 stars	Boost Target	Overweight	$331.00 ➝ $395.00	+21.85%
8/7/2026	Morgan Stanley 3 of 5 stars	Erin Wright 4 of 5 stars	Boost Target	Overweight	$342.00 ➝ $346.00	+7.00%
8/7/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lisa Gill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$382.00 ➝ $390.00	+20.86%
8/6/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold (C+) ➝ Buy (B-)
8/6/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Rodgers Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$370.00	+18.08%
8/6/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kevin Caliendo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$412.00 ➝ $430.00	+35.25%
8/6/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform	$350.00	+10.18%
8/6/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniel Grosslight Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
6/24/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Funk Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$280.00 ➝ $285.00	-0.80%
Get the Latest News and Ratings for COR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Cencora and its competitors with MarketBeat's FREE daily newsletter.
6/10/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Glen Santangelo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$425.00 ➝ $350.00	+25.38%
4/28/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Max Smock Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Market Perform
3/17/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
1/22/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Tanquilut Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underperform ➝ Buy
11/10/2025	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Charles Rhyee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$350.00 ➝ $400.00	+10.23%
11/6/2025	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steven Valiquette Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$340.00 ➝ $380.00	+7.70%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:11 PM ET.

Should I Buy Cencora Stock? COR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, September 24, 2026. Please send any questions or comments about these Cencora pros and cons to contact@marketbeat.com.

Cencora
Bull Case

Here are some ways that investors could benefit from investing in Cencora, Inc.:

Management has expressed strong confidence in the company's specialty-focused strategy, specifically in oncology and retina, which is expected to fuel continued growth into fiscal 2027. This strategy is supported by expanded physician-services capabilities and momentum in international businesses, positioning the company to benefit from pharmaceutical innovation and an aging population.
Cencora, Inc. recently reported strong fiscal third-quarter results with revenue rising 5.1% to $84.8 billion and adjusted earnings per share climbing 12.0% to $4.48. The company also raised its full-year adjusted EPS outlook to a range of $17.75 to $17.95, signaling robust financial performance and operational efficiency.
The company is actively returning capital to shareholders, having repurchased $1 billion of shares in the third quarter and repaid the $800 million term loan related to the Retina Consultants of America acquisition. This aggressive capital allocation strategy, combined with a commitment to growing dividends with earnings, supports shareholder value.
Analysts maintain a Moderate Buy consensus rating with a price target of $370.85, which suggests significant upside potential from the current stock price of $309.53. This valuation gap indicates that the market may not yet fully price in the company's growth trajectory and strategic initiatives.
Short interest in the stock has been declining, with the most recent data showing a decrease to 4,311,607 shares shorted. This reduction in short positions suggests that investors are becoming more confident in the company's outlook and are less likely to bet against its performance.

Cencora
Bear Case

Investors should be bearish about investing in Cencora, Inc. for these reasons:

The stock is currently trading at $309.53, which is significantly below its 52-week high of $377.54. This price action reflects a period of volatility and potential market skepticism, as the stock also recently hit a 52-week low of $244.82 in May 2026, indicating substantial price swings and risk.
There is a reported volume move outside of Cencora, Inc. under its relationship with Walgreens, which became effective July 1. Although executives stated the vast majority of the business remains under the primary contract, this shift will have a wraparound impact on the remaining three quarters of fiscal 2027, potentially affecting revenue and margins.
Prescription utilization trends, which were elevated in 2025, faced pressure during January and February of the current fiscal year. Although utilization rebounded in March, this initial dip highlights the sensitivity of the company's core business to changes in prescription volume and market conditions.
Recent insider activity includes significant share sales, such as CEO Robert P. Mauch selling 5,096 shares in January 2026 and EVP Elizabeth S. Campbell selling 11,300 shares in August 2026. While insider sales can be routine, a pattern of selling may signal a lack of confidence or a desire to diversify holdings among key executives.
The company faces potential regulatory and policy risks, including the effects of the Inflation Reduction Act and early-stage proposals related to the 340B program. Management is working with policymakers to avoid changes that could affect physician economics, but these uncertainties could impact the profitability of its specialty and MSO businesses.

COR Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Cencora is $370.85, with a high forecast of $440.00 and a low forecast of $285.00.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cencora in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" COR shares.

According to analysts, Cencora's stock has a predicted upside of 22.05% based on their 12-month stock forecasts.

Over the previous 90 days, Cencora's stock had 1 upgrade by analysts.

Cencora has been rated by research analysts at Citigroup, Evercore, JPMorgan Chase & Co., Morgan Stanley, Robert W. Baird, Royal Bank Of Canada, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Cencora more than other "healthcare" companies. The consensus rating for Cencora is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how COR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Cencora Recommendations

MarketBeat monitors more than a dozen sources for Cencora analyst ratings, with the most recent rating issued on 9/8/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cencora (COR) Stock Forecast & Price Target